NO2670412T3 - - Google Patents

Info

Publication number
NO2670412T3
NO2670412T3 NO12741560A NO12741560A NO2670412T3 NO 2670412 T3 NO2670412 T3 NO 2670412T3 NO 12741560 A NO12741560 A NO 12741560A NO 12741560 A NO12741560 A NO 12741560A NO 2670412 T3 NO2670412 T3 NO 2670412T3
Authority
NO
Norway
Application number
NO12741560A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011900325A external-priority patent/AU2011900325A0/en
Application filed filed Critical
Publication of NO2670412T3 publication Critical patent/NO2670412T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO12741560A 2011-02-02 2012-02-02 NO2670412T3 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011900325A AU2011900325A0 (en) 2011-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides
PCT/AU2012/000091 WO2012103588A1 (en) 2011-02-02 2012-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides

Publications (1)

Publication Number Publication Date
NO2670412T3 true NO2670412T3 (enExample) 2018-06-02

Family

ID=46602012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12741560A NO2670412T3 (enExample) 2011-02-02 2012-02-02

Country Status (15)

Country Link
US (6) US9101650B2 (enExample)
EP (1) EP2670412B1 (enExample)
JP (1) JP5883458B2 (enExample)
KR (1) KR101840079B1 (enExample)
CN (1) CN103415293B (enExample)
AU (1) AU2012212398B2 (enExample)
CA (1) CA2826166C (enExample)
DK (1) DK2670412T3 (enExample)
ES (1) ES2664611T3 (enExample)
MY (1) MY164728A (enExample)
NO (1) NO2670412T3 (enExample)
PT (1) PT2670412T (enExample)
SG (1) SG192238A1 (enExample)
TW (1) TWI520740B (enExample)
WO (1) WO2012103588A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014339000B2 (en) * 2013-10-22 2017-05-18 Cell Receptor AG Sulfated polysaccharides for use in the treatment of cancer
EP3661524A4 (en) * 2017-08-04 2021-05-05 Paradigm Biopharmaceuticals Limited TREATMENT OF BONE MARROW DISEASES WITH POLYSULFATED POLYSACCHARIDES
CA3089077A1 (en) 2018-02-16 2019-08-22 Proteobioactives Pty Limited Methods and compositions for the treatment of pain and/or inflammation
EP3758717A4 (en) * 2018-02-28 2021-11-24 Paradigm Biopharmaceuticals Limited TREATMENT OF POST-OPERATIVE JOINT PAIN WITH POLYSULFATED POLYSACCHARIDES
FI3863647T3 (fi) * 2018-10-10 2024-03-01 Paradigm Biopharmaceuticals Ltd Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668116A (en) 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
US6593310B1 (en) 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
US6564083B2 (en) * 2000-12-18 2003-05-13 Hoffmann-La Roche Inc. Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis
DE10225551A1 (de) * 2002-06-06 2003-12-24 Schering Ag Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
KR101995016B1 (ko) * 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절

Also Published As

Publication number Publication date
AU2012212398A1 (en) 2013-09-19
WO2012103588A1 (en) 2012-08-09
US20140024614A1 (en) 2014-01-23
DK2670412T3 (en) 2018-03-12
CA2826166A1 (en) 2012-08-09
JP2014504613A (ja) 2014-02-24
SG192238A1 (en) 2013-09-30
CN103415293A (zh) 2013-11-27
ES2664611T3 (es) 2018-04-20
AU2012212398B2 (en) 2014-06-05
KR20140012655A (ko) 2014-02-03
US20240156858A1 (en) 2024-05-16
US10610542B2 (en) 2020-04-07
TW201309307A (zh) 2013-03-01
CA2826166C (en) 2017-05-09
US9861657B2 (en) 2018-01-09
US11406660B2 (en) 2022-08-09
US20220362284A1 (en) 2022-11-17
US20150297633A1 (en) 2015-10-22
JP5883458B2 (ja) 2016-03-15
TWI520740B (zh) 2016-02-11
KR101840079B1 (ko) 2018-03-19
US20210015849A1 (en) 2021-01-21
EP2670412A4 (en) 2015-07-08
EP2670412A1 (en) 2013-12-11
US20180021369A1 (en) 2018-01-25
EP2670412B1 (en) 2018-01-03
US9101650B2 (en) 2015-08-11
MY164728A (en) 2018-01-30
PT2670412T (pt) 2018-03-20
CN103415293B (zh) 2016-08-10

Similar Documents

Publication Publication Date Title
BR112013031251A2 (enExample)
BR112013027245A2 (enExample)
BR112013024383A2 (enExample)
BR112013026905A2 (enExample)
BR112013023185A2 (enExample)
BR112013022995A2 (enExample)
BR112013027830A2 (enExample)
BR112013023927A2 (enExample)
BR112013027452A2 (enExample)
BR112013024365A2 (enExample)
BR112013028733A2 (enExample)
BR112013027121A2 (enExample)
AP2016009466A0 (enExample)
BR112013031556A2 (enExample)
BR112013032368A2 (enExample)
BR112013018949A2 (enExample)
BR112013032377A2 (enExample)
BR112013026895A2 (enExample)
BR112013027761A2 (enExample)
BR112013025487A2 (enExample)
BR112013023266A2 (enExample)
BR112013027112A2 (enExample)
BR112013027657A2 (enExample)
BR112013022499A2 (enExample)
AP3777A (enExample)